Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal
A legfontosabb adatok
- Ki végzi
- Centre Francois Baclesse
- Hol
- Franciaország4 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 46 fő, tervezett
- Kezdés
- 2019. jan. 16.
- Várható befejezés
- 2028. jan.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- FSRT Stereotactic radiation therapy
- A regiszteradat frissítve
- 2025. február 11.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with fewer than 4 brain metastases from a solid tumor, with signs of recent bleeding inside at least one of them. It tests stereotactic radiotherapy (FSRT), a precisely targeted radiation.
- Életkor
- Over 18 years
- Nem
- All sexes
- A betegség stádiuma
- Fewer than 4 brain metastases of a solid tumor (melanoma included), proven by tissue test. Lesions 5 to 30 mm across. At least one shows bleeding signs on CT or MRI. Performance Status 0 or 1. Life expectancy over 6 months. No tumor spread to the brain lining and no brainstem metastasis. A specialist team must approve stereotactic radiotherapy. People who had a metastasis removed and have 1 to 3 brain lesions can join.
- Korábbi kezelés
- No prior stereotactic radiation to the brain and no prior whole-brain radiation. Chemotherapy, hormone therapy, anti-angiogenic and other cancer drugs must stop at least 7 days before FSRT. They can restart 7 days after radiotherapy ends. Immunotherapy does not have to stop.
- Biomarker vagy leletérték
- DS-GPA score by tumor type: lung adenocarcinoma 2 or more; other lung 2.5 or more; kidney 2.5 or more; breast 2.5 or more; digestive cancer 3 or more; melanoma 1.5 or more. Platelets at least 100,000 cells / mm3.
A részvétel fő kizáró okai
- Small cell lung cancer, germ cell tumors, lymphoma, leukemia or multiple myeloma
- Blood thinners or anti-platelet drugs during FSRT, unless they can stop 5 days before and restart 2 weeks after
- Cannot have brain MRI or gadolinium contrast
- Bleeding disorders other than bleeding inside the brain tumor
- Neurodegenerative disease, or a disease making tissue more sensitive to radiation (such as neurofibromatosis)
A regiszter feltételei, szó szerint
Mind a 30 feltétel megnézéseKevesebb
Ki vehet részt
- Age> 18 years
- Performance Status 0 or 1
- Patient with less than 4 brain metastases [of a solid tumor, including melanoma, with a histologically proven diagnosis for the solid tumor; Patients who have had a metastasectomy and 1 to 3 brain metastatic lesions are eligible
- Brain injury (s) measuring between 5 and 30 mm in diameter
- Patient eligible for stereotactic radiotherapy after a decision of the multidisciplinary committee
- Presence of intra-tumor bleeding signals on at least one brain injury before stereotactic irradiation and defined by :; hyperdense lesion on the non-injected CT (treatment scanner) and / or,; spontaneously hyperintense lesion on T1 MRI sequences without gadolinium injection and / or,; lesion with hypo signal on T2 sequences *
- Absence of meningeal tumor invasion
- Absence of brainstem metastasis
- DS-GPA depending on the histological type (https://brainmetgpa.com/#start):; Lung Adecarcinoma: DS-GPA 2 or +; Non-adenocarcinoma lung: DS-GPA 2.5 or +; Kidney: DS-GPA 2.5 or +; Breast: DS-GPA 2.5 or +; Digestive cancer: DS-GPA 3 or +; Melanoma: DS-GPA 1.5 or +
- Patient without concomitant anti-cancer therapy (chemotherapy, hormone therapy, anti-angiogenic or other anti-cancer treatments). Treatments should be suspended for at least 7 days before the start of FSRT radiotherapy. The treatment can be resumed 7 days after the end of radiotherapy. It's not mandatory to suspend immunotherapy
- Life expectancy estimated at over 6 months
- Patient cooperating sufficiently to perform the treatment with the use of a thermoformed mask
- Patient whose neuropsychological capacities make it possible to follow the requirements of the protocol
- Patient affiliated to a social security scheme
- Patient giving written consent
Ki nem vehet részt
- Patient with a concomitant neurodegenerative disease
- Any symptoms not attributable to cerebral metastasis or cancerous pathology and requiring long-term use of corticosteroids (regardless of dose)
- Planning of the treatment on the target metastasis delivering a dose> 5 Gy on other metastases concomitant
- Patient with prior cerebral stereotactic irradiation
- Patient with small cell lung cancer, germ cell tumors, lymphoma, leukemia and multiple myeloma
- Hemorrhagic disorders other than intra-tumor bleeding from brain lesion (s)
- Radiosensitizing systemic disease (Neurofibromatosis ...)
- History of total brain irradiation
- Any associated geographical, social or psychopathological condition that could compromise the patient's ability to participate in the study
- Anticoagulant treatment, and / or anti-platelet aggregation with curative et prophylaxic dose during FSRT. If treatment can be delayed for at least 5 days before starting FSRT and resumed 2 weeks after completion of FSRT, the patient is eligible
- Contraindication to brain MRI or gadolinium injection
- Thrombocytopenia less than 100,000 cells / mm3
- Hemorrhagic metastasis (s) of the brainstem
- Participation in a therapeutic trial that could compromise the conduct of study
- Patient deprived of liberty or under guardianship
Ez a vizsgálat jelenleg itt érhető el: Franciaország.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases
A vizsgálat csoportja
- FSRT Stereotactic radiation therapyA vizsgált kezelés
Each cerebral metastasis (hemorrhagic or otherwise) will be treated by radiation
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Stereotactic Radiotherapy for Cerebral Metastases with Recent Hemorrhagic Signal: Phase 2 Study in 2 Steps
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- Publikációk
- A regiszteradat frissítve
- 2025. február 11.